期刊文献+

国产阿立哌唑治疗精神分裂症的临床观察 被引量:3

下载PDF
导出
摘要 目的验证国产阿立哌唑片(博思清)治疗精神分裂症的临床疗效和安全性。方法随机入组首发或症状急性恶化的精神分裂症患者43例(男∶女=18∶25),运用阿立哌唑治疗,剂量为(18.9±7.4)mg/d,临床观察6周。采用阳性症状与阴性症状量表(PANSS)评定疗效,不良反应症状量表(TESS),血生化指标、心电图和体重改变评价治疗的安全性。结果治疗2周后,PANSS阳性、阴性症状分和总分均显著下降(P<0.05);治疗6周后PANSS各分值(阳性症状分:13.0±5.91,阴性症状分:14.8±8.4,总分:56.4±20.6)与基线水平(阳性症状分:22.1±7.6,阴性症状分:22.3±9.1,总分:88.7±16.1)差异显著(P<0.001);经6周治疗,基本痊愈9例,占21%,显著进步+好转共23例,占53%,症状无显著变化10例,占24%,1例患者病情有不同程度恶化;治疗过程中,所有患者TESS总分最大值(3.6±4.3),不良反应的发生率为60%;6周的观察中未发现阿立哌唑导致的体重显著增加和心电图的明显改变。结论国产阿立哌唑(博思清)对精神分裂症的疗效肯定,安全性良好。
机构地区 北京回龙观医院
出处 《神经疾病与精神卫生》 2007年第3期213-215,共3页 Journal of Neuroscience and Mental Health
  • 相关文献

参考文献12

  • 1Meltzer HY,Zhu Li,Yasuhiro Kaneda,et al.Serotonin receptors:their key role in drugs to treat schizophrenia[J].Progress in Neuro Psychopharmacology Biological Psychiatry,2003,(27):1159-1172.
  • 2Fuji Yokoi,Gerhard Gr nder,Kathleen Biziere,et al.Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597):A Study Using Positron Emission Tomography and[ 11C]Raclopride[J].Neuropharmacology,2002,27:148-158.
  • 3Shaun J,Vuk K,Ruoyan C,et al.The antipsychotic aripiprazole is a potent,partial agonistat the human 5-HT1A receptor[J].European Journal of Pharmacology,2002,441:137-140.
  • 4Stephen RM,Robert DM,Elyse S,et al.Aripiprazole in the treatment of schizophrenia:safety and tolerability in short-term,placebo-controlled trials[J].Schizophrenia Research,2003,61:123-136.
  • 5Anthony D,Nick Cpatel,Lynn C.Aripiprazole:A Comprehensive Review of Its Pharmacology,Clinical Efficacy,andTolerability[J].Clinical Therapeutics,2004,26:649-666.
  • 6韦盛中.阿立哌唑与舒必利治疗精神分裂症阴性症状对照研究[J].神经疾病与精神卫生,2006,6(4):264-266. 被引量:6
  • 7Petrie JL,Saha AR,McEvoy JP,et al.Aripiprazole,a new atypical antipsychotic:Phase 2 clinical trial result[J].Psychotic disorder and antipsychotic,2002,P2:S227.
  • 8麦桂英,蔡广惠,黄金满,李英,何广贤,戴俊平.阿立哌唑与利培酮治疗精神分裂症的对照研究[J].中国康复,2005,20(3):184-185. 被引量:32
  • 9符传创,刘学兵,卢佩贤,郑庆梅,杨光.阿立哌唑治疗首发精神分裂症30例临床观察[J].海南医学,2005,16(6):112-112. 被引量:21
  • 10John WN.Metabolic Risk During Antipsychotic Treatment[J].Clinical Therapeutics,2004,26:1936-1956.

二级参考文献26

共引文献145

同被引文献36

  • 1吴仁容,李乐华.新型抗精神病药:阿立哌唑[J].国外医学(精神病学分册),2004,31(3):177-179. 被引量:380
  • 2邹豪,邵元福,朱才娟,邓渝林,马玉杰,陈盛新.医院药品DDD数排序分析的原理及利用[J].中国药房,1996,7(5):215-217. 被引量:1426
  • 3Jockers-Scherubl M,Godemann F,Pietzcker A.Negative symptoms of schizophrenia are improve by paroxetine added to neuroleptics a pilot study[J].J Clin Psychiatry,2001,62(7):573.
  • 4Bolden-Watson C,Michelson E.Blockade by newly-developed antidepressant of biogenic amine Uptake into rat brain synaptosomes[J].Life Sci,1993,52(12):1023-1025.
  • 5Guelfi JD,White C,Hackett D,et al.Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia[J].J Clin Psychiatry,1995,56(10):450-458.
  • 6Lecrubier Y,Bourin M,Moon CA,et al.Efficacy of venlafaxine in depressive illness in general Practice[J].Acta Psychiatry Scand,1997,95(6):485-493.
  • 7Rudolph RL,Fabre LF,Felghner JP,et al.A randomized,Placebo-controlled,Close-response trial of venlafaxine hydrochloride in the treatment of major depression[J].J Clin Psychiatry,1988,59(3):116-122.
  • 8汪向东,王希林,马弘.心理卫生评定量表手册[S].增订版.中国心理卫生杂志社,1999:267-275.
  • 9Guy W.Ecdeu Assessment Manual for Psychopharmacology.Revised[M].USA:Rockville DEW,1976:341-350.
  • 10张明园.精神科评定量表手册[S].长沙:科学技术出版社,2003:94-275.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部